• Automation solutions are transforming the $300 billion U.S. hospitality industry, from tasks to personalizing guest experiences
• Nightfood Holdings, through its subsidiary Future Hospitality Ventures (“FHV”), is leading the charge in AI-powered hospitality solutions, aiming to enable hospitality operators to survive in a threatening environment
• FHV is integrating AI and machine learning into the industry to streamline operations and deliver exceptional service, overcoming some of the industry’s top challenges

The hospitality industry is undergoing a radical transformation, forced upon it by the need to compete for survival. This revolution is driven by the rapid advancement of technological intelligence.

Many believe the benefits of AI are so profound, that only two types of hospitality operators will exist soon: Those that were early adopters, and those that are out of business.

One of the most significant applications of AI is its ability to automate routine tasks and improve efficiency. AI-powered bots can handle inquiries, freeing up staff to focus on more complex, human-like tasks. This technology can analyze vast amounts of data to identify trends and optimize pricing strategies, ultimately helping businesses from going under at such an early period.

Another key area where AI is making a difference is in personalization. By leveraging AI-powered CRM systems, businesses can gain a deeper understanding of their guests’ preferences and tailor their services accordingly. This can lead to increased customer satisfaction and loyalty, and ultimately long-term success. 

As this revolution plays out in real time, it’s crucial for these entrepreneurs to embrace AI technology before the industry moves on without them. By investing in AI-powered solutions, employers can stay competitive, improve efficiency in every region, and save their business.

The Evolving Landscape of Hospitality

The need to modernize has been fueled by labor shortages and rising costs plaguing the $300 billion U.S. hospitality industry. Nightfood Holdings (OTCQB: NGTF), through its subsidiary Future Hospitality Ventures (Future Hospitality), is pioneering Robots-as-a-Service (“RaaS”).

The hospitality industry is undergoing a tectonic shift. Future Hospitality is using automation to solve the labor crisis. The key is lowering barriers to entry for hospitality operators, allowing them to automate, survive and thrive.

Looking Ahead

Future Hospitality is actively collaborating with leading robotics providers to develop and deliver cutting-edge autonomous driven solutions. These collaborations are expected to yield industry-revolutionizing innovations that will forever alter the economic landscape of this industry.

Future Hospitality’s ambitious plans will focus initially on the popular Los Angeles area before expanding nationwide, bringing its novel solutions to hospitality venues across the country.

“The hospitality industry is at a technological crossroads where operators slow to adapt will be left behind,” said Sonny Wang, President of Future Hospitality. “We’ve seen similar patterns in other industries such as automotive, construction and real estate. This upheaval means tremendous opportunity for innovative solutions providers like Future Hospitality.”

When external forces and mega-trends force industry upheaval, windows of opportunity exist. The coming automation revolution is set to radically alter this $300 billion dollar industry.

For more information, visit the company’s website at NightfoodHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Established in 1920, Superior Group of Companies (NASDAQ: SGC) is comprised of three attractive business segments each serving large, fragmented and growing addressable markets. Across healthcare apparel, branded products and contact centers, each segment enables businesses to create extraordinary brand engagement experiences for their customers and employees. SGC’s commitment to service, quality, advanced technology, and omnichannel commerce provides unparalleled competitive advantages. SGC is committed to enhancing shareholder value by continuing to pursue a combination of organic growth and strategic acquisitions. For more information, visit the company’s website at www.superiorgroupofcompanies.com.

To view IBN’s virtual coverage of Noble’s 20th annual small and micro-cap investor conference, visit https://ibn.fm/NobleCon20

About IBN’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating at this year’s NobleCon. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• Discovering viable gold deposits involves advanced geoscientific techniques, significant financial investment and years of rigorous exploration and development.
• Torr Metals, an emerging player in the mining sector, is making significant strides in gold exploration with its Filion project.
• The company recently announced that it had organized field crews to undertake a large-scale surface exploration program at Filion.

Gold has long been a cornerstone of global economic stability, acting as both a store of value and a hedge against inflation. For centuries, this precious metal has provided a haven during economic downturns and geopolitical uncertainties. Central banks hold vast reserves of gold to underpin their currencies, and investors flock to it during times of market volatility. Despite gold’s central role in economic stability and as a haven, major new discoveries are rapidly decreasing due to a decades-long focus on previously drilled early-stage exploration projects that have yet to deliver just as existing deposits are declining in grade and productivity. With future gold resources shrinking, the need for fresh new discoveries has never been more urgent, highlighting the critical value of skilled leadership with a proven track record in exploration to identify new, economically viable deposits. Torr Metals (TSX.V: TMET), a mineral exploration company, is poised to deliver a potential new gold discovery adjacent to the Trans-Canada Highway 11 as it develops its northern Ontario-based 261 km² Filion Gold Project (https://ibn.fm/J8Mlx).

Pioneering Exploration at Filion Backed by Proven Leadership

Amid this backdrop, Torr Metals is advancing exploration at its extensive 261 km² Filion Gold Project, aiming to unlock new greenfield gold potential. Encompassing an entire prospective greenstone belt and located conveniently along the Trans-Canada Highway, the Filion Project draws interesting parallels to the famed Hemlo gold deposit to the south, which was similarly situated before its landmark discovery and successive staking rush in the 1980s.

Torr Metals is taking a meticulous, strategic approach to its first year of exploration at the Filion Gold Project, employing phased exploration designed to maximize potential while mitigating risk. The company’s discovery of an undrilled 1.2-kilometer gold soil anomaly along the Trans-Canada Highway is particularly significant, given the rarity of finding such substantial undrilled mineralization, with high-grades up to 1.32 g/t gold, in a greenfield setting backed by substantial easy access to provincial and nearby mining infrastructure. This approach underscores Torr Metals’ commitment to discovery, marking a significant achievement by defining widespread gold mineralization in an area that others have overlooked.

Torr’s programs at Filion incorporates high-resolution geophysical surveys and geochemical sampling, laying a robust foundation for defining subsurface gold-bearing structures and guiding potential drill targeting. Most recently, the company announced that it had organized field crews to undertake a large-scale surface exploration program at Filion, including soil sampling and prospecting (https://ibn.fm/4pvYX). The extensive surface exploration is focused on 9 square kilometers of highly prospective and largely underexplored ground that could potentially expand on the initial 2024 soil anomalies while further delineating promising gold-bearing zones, setting the stage for a carefully planned maiden drill program that will be the first to drill these targets.

“We’re thrilled to mobilize field crews to the Filion Gold Project, where the untapped exploration potential is vast, spanning an unexplored 42 km structural corridor known for hosting high-grade gold,” said Malcolm Dorsey, president and CEO of Torr Metals. “Our 2024 program will focus on testing unexamined conductors, historical gold occurrences, and advancing the significant anomalies from 2023. Combined with new LiDAR data revealing untested outcrops and undrilled high-priority targets, this large-scale effort sets the stage for major grassroots discoveries in this highly prospective but underexplored region.”

Add to this an unmatched team of seasoned professionals, each bringing invaluable experience and a proven track record in the mining sector. Torr Metals is led by President and CEO Malcolm Dorsey, a dynamic exploration geologist with over a decade of success in advancing copper and gold projects from early-stages through to resource definition. Malcolm’s expertise and ability to generate projects through low staking costs greatly strengthened the company’s strategic vision and brought the Filion and Kolos projects into Torr’s portfolio with 100% ownership. Chairman John Williamson has raised nearly $1 billion in capital for exploration projects globally and played pivotal roles in discovering over 10 million ounces of gold across three continents. With 35 years in the industry, John has consistently driven ventures to TSX Venture 50(TM) recognition. Complementing them is Gordon Maxwell, a veteran geologist with nearly 40 years of global exploration management experience with Noranda, Xstrata and most recently Glencore, where he also served as business development manager. Together, this team combines extensive expertise, strategic foresight and relentless drive to propel Torr Metals toward success.

The Future of Gold Exploration with Torr Metals

Torr Metals exemplifies the determination and innovation required to tackle the challenges of modern gold exploration. The company’s efforts at Filion are setting the stage for a potentially significant gold discovery, which could bolster global supplies and provide economic benefits to the local community. As the world continues to rely on gold as a pillar of financial security, the work of companies such as Torr Metals is crucial.

In a highly competitive market where finding new gold resources is becoming increasingly difficult, Torr’s focus on exploring untapped, high-potential ground gives the company a unique edge. By uncovering mineralization in previously unexplored regions, Torr is in a prime position to unlock the next gold frontier in which it already holds a commanding land position, setting itself apart from competitors and positioning itself for potential success in an industry where new greenfield discoveries are becoming a necessity. As the Filion project progresses, it will be one to watch for both industry stakeholders and investors seeking exposure to the next wave of gold discoveries.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

The Social Media Strategies Summit for Public Agencies & Government Organizations will be held on December 10-12, 2024, as a virtual conference. Executives and professionals managing social media channels of their public and government agencies are invited to attend the event.

SMSS is a networking platform that focuses on a niche audience of decision-makers, influencers, marketers, and professionals from the social media spectrum. Digital marketing experts and professionals will share effective tips and time-tested strategies for engagement with a targeted audience.

The event will commence on December 10 with a pre-summit workshop that will be conducted by experts who will discuss all aspects of social media marketing. The summit will be held on December 11-12, 2024, with live streaming sessions, 30-minute talks and panels, along with a 15-minute Q & A session among the speakers and the audience.

Experts hosting the panels and speaker sessions will discuss several important topics that impact the agency’s social media outreach, including ways of overcoming barriers to make decisions based on the audience’s feedback, and how to run successful social media campaigns on tight budgets.

During the panel discussions, the audience can ask direct questions about particular challenges regarding social media marketing and learn ways to balance their professional and personal messaging. One of the sessions is dedicated to Canva, a versatile and user-friendly graphic design platform used for creating stunning visual content without requiring professional design knowledge.

Attendees will also learn insights into leveraging social media platforms to increase their organization’s reach, reputation and engagement with their target audience. They can share experiences and knowledge with peers attending the event. Respected professionals of the social media marketing realm will share actual case studies and discuss the most effective strategies to enable marketers to humanize their agency and build trust.

To learn more, please visit https://ibn.fm/W0qWo.

• Annovis provided business and financial updates for Q3 2024, spotlighting progress toward pivotal buntanetap trials in Alzheimer’s disease.
• The FDA has cleared Annovis to proceed with a Phase 3 program, which will include a 6-month study to confirm buntanetap’s symptomatic benefits (beginning Q1 2025) and an 18-month study to explore potential disease-modifying effects.
• Matthew Peterson, Ph.D., was appointed as Senior Clinical Scientist and will oversee quality and rigor in upcoming clinical trials.
• Annovis filed three new patents for innovative combination therapies, involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), and a combination of all three.
• As of Nov. 8, 2024, the company reported a cash position of $13.6 million, providing sufficient runway to support all Phase 3 preparatory activities and to initiate the pivotal Phase 3 Alzheimer’s study in Q1 2025.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), concluded the third quarter with significant milestones achieved and a clear path forward for its lead candidate, buntanetap.

Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying, positioning buntanetap as a potential breakthrough in treating neurodegenerative diseases.

The drug candidate has been shown effective in improving the health of nerve cells and therefore cognition in AD and cognition and motor function in PD patients. Annovis recently completed a Phase 2/3 AD study, with encouraging results that were presented to the U.S. Food and Drug Administration (“FDA”) on Oct. 10, 2024. During that meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies: a 6-month study aimed at confirming buntanetap’s symptomatic effects, set to begin in Q1 2025, and an 18-month study designed to demonstrate potential disease-modifying effects. The FDA also recognized buntanetap’s safety, raising no concerns regarding liver enzyme levels, drug interactions, dose selection, pharmacokinetics, population pharmacokinetics and confirmed that development could proceed using the new crystal form of buntanetap.

To ensure the successful completion of upcoming clinical trials, the company appointed Matthew Peterson, Ph.D., as Senior Clinical Scientist, who will be responsible for quality and rigor in the next studies.

“The third quarter was a milestone period that has clearly defined our path forward for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “With FDA approval to launch confirmatory Phase 3 studies in early AD, our team is focused on initiating a 6-month pivotal trial early next year. We also bolstered our IP portfolio with new patents for combination therapies involving buntanetap, reinforcing our commitment to finding innovative solutions for these debilitating conditions.”

The three new patents, filed on Sept. 30, 2024, cover combination therapies involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, creating a multifaceted approach to treating neurodegenerative diseases.

During the third quarter, Annovis presented two posters at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid, showcasing buntanetap’s efficacy in Phase 2/3 AD study and the biomarker data.

In terms of Q3 financial results, the company announced that it has an adequate runway for all Phase 3 preparatory studies and for entering the pivotal Phase 3 AD study in Q1 2025, having cash and cash equivalents of $13.6 million as of Nov. 8, 2024.

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

The 13th Annual ROTH Technology Conference, hosted by investment bank Roth Capital Partners, is set to bring together innovative technology companies and investors on November 19-20, 2024, at the Hard Rock Hotel in New York City. This exclusive, by-invitation-only event will provide a focused platform for capital sources and entrepreneurs to connect, explore potential partnerships, and pursue financial growth opportunities in the technology industry.

Approximately 100 growth-oriented technology companies will be represented by their executive teams, with an additional dozen companies invited to participate. Attendees will engage in 40-minute, pre-arranged one-on-one and small-group meetings to discuss investment opportunities, capped by an evening networking social on the first day.

The event will showcase companies from key technology sectors, including software and enterprise applications, data analytics and AI, digital media, semiconductors, data infrastructure, intelligent systems, and IoT and wireless communication technologies. Confirmed attendees range across the industry spectrum, from A2Z Cust2Mate Solutions to Zeta Global Holdings Corp.

ROTH’s Managing Director and Chief Technical Strategist, JC O’Hara, will provide expert insights on technology’s role in the global market, drawing on his extensive research in analyzing asset performance and market trends.

Key Highlights:

• Exclusive location in New York City, the global financial hub.
• Two days of targeted, pre-qualified investor meetings with high-growth technology companies.
• Expert market analysis from JC O’Hara, ROTH’s Chief Technical Strategist.
• Networking opportunities through structured meetings and social gatherings.
• Participation from approximately 100 leading technology companies.

For more information about this event and to request a registration opportunity, please visit https://ibn.fm/LxiQX

• Kairos Pharma’s partnership with Cedars-Sinai Medical Center enhances clinical trial efficiency and accelerates the development of new therapeutic solutions.
• The company holds a robust intellectual property portfolio with patents extending through 2040, providing a strong competitive advantage in the oncology market.
• ENV105, Kairos’s lead drug candidate, shows promise in reversing drug resistance in prostate and lung cancers, addressing key markets with high demand for novel treatments.
• Positioned in high-growth oncology segments, Kairos Pharma meets substantial market needs, driven by the increasing global incidence of drug-resistant cancers.
• The company’s focus on biomarker development improves patient targeting, enhancing therapy success rates and underscoring its commitment to precision medicine.

Kairos Pharma (NYSE American: KAPA) is a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics that target drug resistance and immune suppression, two significant barriers in effective cancer treatment. By addressing these mechanisms, Kairos aims to restore the efficacy of standard cancer treatments while enhancing the body’s natural immune responses against tumors.

The company’s mission is to develop a diverse portfolio of drug candidates to provide novel options for patients with limited treatment pathways. Kairos is advancing its therapeutic pipeline with a focus on partnerships, precision medicine and clinical trial efficiency, moving closer to delivering new solutions for durable cancer remissions and improved patient quality of life.

Headquartered in Los Angeles, California, Kairos Pharma combines research excellence with patient-centered care. Led by an accomplished team of scientists and executives, the company is committed to transforming the cancer treatment landscape through next-generation therapeutic solutions that meet the highest standards of efficacy and safety.

Development Pipeline

Kairos Pharma’s development pipeline features multiple candidates across clinical and preclinical stages, each targeting unique mechanisms of resistance to cancer treatment:

• ENV105: Currently in a Phase 2 trial for castrate-resistant prostate cancer, ENV105 is administered in combination with Apalutamide to overcome anti-androgen resistance. The company recently dosed the first patient in this trial, marking an important milestone in advancing prostate cancer treatment. ENV105 is also in a Phase 1 trial for EGFR-driven non-small cell lung cancer, where it is combined with Osimertinib to address resistance in this hard-to-treat cancer type. Kairos’s partnership with PreCheck Health Services supports the confirmation of biomarkers to identify patients most likely to benefit from ENV105, enhancing precision in patient selection.
• KROS201: This candidate has received IND clearance for glioblastoma and focuses on activating T cells outside the body to target and destroy tumor cells, specifically addressing aggressive and treatment-resistant cancers.
• KROS101: Designed to increase the number and efficacy of T cells, KROS101 shows promise in enhancing the immune system’s response to cancer, complementing existing immunotherapies.
• KROS102: Targeted at autoimmune diseases, KROS102 works by decreasing T cell activity, potentially offering a new approach to managing autoimmune conditions.
• KROS301 and KROS401: These candidates focus on inhibiting cancer cell growth and mitigating immune suppression in advanced cancers, including triple-negative breast cancer.

Intellectual Property Portfolio

Kairos Pharma’s intellectual property portfolio secures exclusive rights to its advanced drug technologies and forms the backbone of its innovative approach in oncology. Key patents cover ENV105, protecting its mechanism of targeting CD105 to reverse resistance in prostate and lung cancers. This IP extends internationally and is valid until 2040, ensuring a secure competitive position in the cancer therapeutics market.

Additionally, Kairos’s portfolio includes patents for the KROS series (KROS101, KROS201, KROS301, and KROS401), covering applications in both cancer and autoimmune diseases. Many of these patents were developed through research at Cedars-Sinai Medical Center, from which Kairos holds exclusive, worldwide licensing rights. This robust IP framework positions the company to leverage its unique technologies across multiple therapeutic areas, with a clear focus on addressing unmet medical needs in cancer and immune-related conditions.

Market Opportunity

Kairos Pharma is positioned to address high-growth oncology markets that demand innovative solutions to overcome drug resistance. The prostate cancer market, estimated at $11.3 billion, and the EGFR-driven lung cancer market, valued at $14 billion, represent key segments where Kairos’s drug candidates, particularly ENV105, have significant potential. Rising cancer incidence globally further underscores the demand for effective treatments that can restore sensitivity to existing therapies.

The broader immunotherapy market, which is projected to reach up to $148 billion by 2030, represents another major growth area for Kairos Pharma. The company’s targeted approach aligns with the precision medicine trend in oncology, enabling the development of therapies tailored to patient needs. By addressing underserved areas in cancer treatment, Kairos is poised to meet substantial unmet needs in the oncology and immunotherapy markets.

Leadership Team

Dr. John S. Yu serves as CEO and Chairman of Kairos Pharma. An accomplished neurosurgeon and immunotherapy expert, Dr. Yu has developed numerous investigational drugs and led multiple clinical trials. He holds degrees from Stanford, Harvard Medical School and MIT, and his career is centered on groundbreaking research in cancer therapeutics.

Dr. Neil Bhowmick, Chief Scientific Officer, brings over 20 years of extensive biochemistry expertise, including filing and prosecuting patents for therapeutics and devices, authoring 110 peer-reviewed publications, and leading foundational and pre-clinical cancer research. He has successfully obtained regulatory approvals and conducted clinical trials. With more than 15 years of continuous NCI/NIH funding, Dr. Bhowmick’s work has been cited over 15,000 times. He holds six patents, including innovations in biomarker detection platforms and stromal-targeted therapeutics such as ENV 105 and ENV 205.

Dr. Ramchandran Murali, VP of Research and Development, is an immunologist and molecular engineer recognized for his work in developing pharmacological agents to counter immune suppression in cancer. His extensive research background is instrumental in advancing Kairos’s innovative drug pipeline.

Doug Samuelson, Chief Financial Officer, brings over 25 years of experience in finance, having served as CFO for various biopharma companies. His expertise in financial management and regulatory compliance provides strong support to Kairos Pharma’s strategic initiatives as a clinical-stage company.

For more information, visit the company’s website at KairosPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA          

• Alcohol screening and monitoring solutions provider SOBRsafe recently closed on a private placement, which raised $8.2 million in gross proceeds
• The company plans to use the net proceeds from the private placement for working capital and general corporate purposes, including possibly boosting its expansion efforts
• With an ongoing national marketing campaign, SOBRsafe is presenting its revolutionary alcohol screening and monitoring technologies to 45,000 behavioral health providers in the U.S.
• In addition, the company initiated sales activities in Australia and New Zealand through a partnership with a channel partner, and is partnering with companies in India and Italy for proof-of-concept installations of SOBRcheck(TM) or SOBRsure(TM)

SOBRsafe (NASDAQ: SOBR), a provider of next-generation transdermal alcohol screening and monitoring solutions, recently raised $8.2 million in gross proceeds from a private placement with certain institutional investors. The company expects to use the net proceeds from the offering for working capital and general corporate purposes (https://ibn.fm/xM074).

The closing of this offering, announced on October 9, came amid the company’s ongoing expansion efforts, with some of the proceeds expected to boost these initiatives. In August, SOBRsafe launched a national campaign that seeks to introduce the company’s technology offerings – the SOBRcheck(TM) stationary alcohol screening device, the SOBRsure(TM) discreet alcohol monitoring wristband, and the SOBRsafe(TM) software platform powering reporting – to behavioral health providers and, as a result, drive sales growth into 2025.

The company aims to present its technology to over 45,000 decision-makers in the behavioral health space, having partnered with recognized leaders in public relations and digital and social media marketing. “We are working with national communications leaders to build the SOBRsafe brand, grow demand, and gain market share. This effort will move us closer to improving patient outcomes and saving lives,” said SOBRsafe CEO and Chairman Dave Gandini of the national campaign (https://ibn.fm/8DTo2).

The campaign aligns with the company’s focus on the behavioral health vertical. In addition, it is intended to increase the number of customer accounts that SOBRsafe has added in 2024, which stood at 35 as of September 12. The company accomplished this feat with “a limited investment in marketing and brand building,” according to Gandini’s message in a recent video update (https://ibn.fm/V0uKi). The ongoing national campaign, therefore, may result in considerably more customer accounts during the remainder of 2024 and into 2025.

SOBRsafe is also strategically implementing its international expansion. Strategic in its approach, the company collaborates with interested local or regional service providers and companies, initially via paid proofs of concept and, if successful, fully fledged partnerships. The company has used – or is using – this approach in India, Italy, Australia, and New Zealand.

In India, a critical infrastructure developer that owns and operates various infrastructure assets across India and Southeast Asia is installing SOBRsafe’s SOBRcheck(TM) device at points of entry to screen employees. This paid proof-of-concept installation is intended to promote alcohol safety, helping SOBRsafe “establish a new standard for alcohol screening in India” and provide “value to employers while saving lives,” according to Gandini (https://ibn.fm/40AHH).

An employer in Italy has also selected the company’s SOBRsure(TM) wristband for remote continuous monitoring of fleet drivers. This proof-of-concept application of the device will help verify both the location and sobriety of drivers, benefiting the company, which operates a fleet of more than 10,000 vehicles. Gandini believes SOBRsure “can help European employers demonstrate compliance” with laws prohibiting commercial drivers from imbibing any amount of alcohol and do so in real-time and in a “passive, non-invasive manner.”

The proof-of-concept approach has proven successful in Australia and New Zealand, where, after a 90-day trial run, SOBRsafe initiated sales activities via a regional channel partner, Drug Testing Business Success. The channel partner plans to target the behavioral and justice spaces, availing the company’s products through a dedicated e-commerce website and a coalition of suppliers. “We’re excited about this new revenue stream in Australia and New Zealand, and we believe that this could accelerate broader global expansion,” conveyed Gandini (https://ibn.fm/IVmHi).

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

Cogna, an artificial intelligence software firm, just brought in $15 million in new backing. The company has the largest gas distribution network in Britain among its clients. This latest funding includes investment from key venture capital firms Chalfen Ventures and Notion Capital.

Cogna intends to use the funding to boost productivity and resolve inefficiencies within the operations of their target clientele. According to the company, they intend to use “precision solutions” in the diagnosis and fixing of those challenges faced by their customers. Their clients are currently within the manufacturing, utilities and energy sectors.

With this new funding, Cogna plans to spread its reach to customers within other industries. They also plan to broaden the scope of their automated artificial intelligence-supported factory making software solutions.

Currently, Cogna is making inroads into the enterprise resource planning niche as well as the market for IT consultancy services. These industries are currently worth $51 billion and $362.5 billion in revenue, respectively. Cogna CEO and co-founder Ben Peters said that traditional manufacturing industries had been sidelined by the digital revolution as a result of the complex and peculiar challenges that they faced. He added that Cogna was determined to design solutions tailored to the unique needs of manufacturing industries so that they, too, can register the productivity enhancement that AI solutions can deliver.

Peters expressed confidence that the new funding injected into Cogna would enable the company to address the different bottlenecks which have been holding back entities in different industries, and the AI solutions would allow employees to unlock their potential once mundane repetitive tasks were taken over by automated AI solutions.

Howard Forster, COO of Cadent Gas, said that with network piping to the tune of 82,000 miles and over 11 million customers, they needed a software provider that could match their physical infrastructure scale. Cogna was suited to their requirements and they were happy to work with the company to develop solutions for various needs, such as optimizing their procurement system and creating a system to manage gas escape.

As more companies like Cogna bring AI solutions to different industries and sectors, the rate at which AI penetrates different walks of life is bound to accelerate. As that happens, the infrastructure demand (data centers and system components) will grow. Metals like copper, silver and gold are crucial to this expansion and mining entities like McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) are well positioned to reap from the ongoing AI boom.

For more information, visit the company’s website at www.McEwenMining.com

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• “Gold has value beyond its appreciated aesthetics; gold is a very unique precious metal,” Forbes reports.
• In its recent update to shareholders, Renforth Resources noted key progress in its gold-exploration efforts.
• Findings “demonstrate the potential of our properties” and speak to “the immense opportunity ahead,” notes CEO.

Long an essential component of a healthy global economy, gold has steadily increased in value since the turn of the century. Companies operating in gold exploration and mining, such as Renforth Resources (CSE: RFR) (OTCQB: RFHRF), play a key role in discovering and supplying gold. Renforth Resources recently strengthened its position in the gold space with an update on significant gold exploration advances at two of its properties (https://ibn.fm/TlV99).

A recent Forbes article outlined why gold is so valuable in today’s world (https://ibn.fm/fMAtz). “Gold has historically been seen as a stable hedge against economic instability or recession,” the article said. “For that reason, many investors and even countries purchase gold to diversify their investments and achieve economic stability.”

In addition, the article noted that gold is a key element in global socioeconomic trends, jewelry and electronics. “As rising middle classes in emerging markets like China, India and southeast Asia grow their wealth, the demand for gold, particularly in jewelry and as an investment, continues to rise. This demographic shift contributes significantly to the sustained demand and value of gold globally,” the article stated.

“Gold has value beyond its appreciated aesthetics; gold is a very unique precious metal,” the article continued. “Gold doesn’t corrode or tarnish and is a soft material which can be easily drawn out into narrow wires or plated into thin coatings. These qualities make gold an exceptional choice for use in electronics, circuit boards, electric vehicles, healthcare equipment and other vital technology sectors.” Forbes also pointed out that “gold is a finite resource with a limited supply we continue to utilize.”

In its recent update to shareholders, Renforth Resources noted key progress in its gold-exploration efforts. “At the Beaupré project, a soil sampling program has revealed a significant gold anomaly of 0.37g/t Au in a soil sample,” the report stated. “At Renforth’s wholly owned Parbec gold deposit, follow-up soil sampling has been completed, and prospecting has identified and sampled bedrock at the site of a previously detected 0.28g/t Au soil anomaly. These findings represent significant progress in Renforth’s ongoing exploration efforts across its multicommodity mineral portfolio.”

Renforth president and CEO Nicole Brewster stated: “We are encouraged by our continued exploration success, including the recent gold anomaly discovery at Beaupré and the promising visual results from our follow-up work at Parbec. These findings again demonstrate the potential of our properties; continued success in identifying gold mineralization, particularly in underexplored areas, speaks to the immense opportunity ahead. We remain committed to advancing our gold assets, both Beaupré and Parbec, at the same time as we focus on derisking and developing our nearby Victoria critical minerals project.”

Renforth Resources is an active mineral-exploration company engaged in the exploration and development of the company’s wholly owned multicommodity mineral properties in Canada. The company owns the Parbec gold deposit on the Cadillac Break in Quebec and is currently exploring the Parbec property to increase the gold resource and identify a location to strip and bulk sample from surface.

In addition, the company holds the Nixon Bartleman gold property in Ontario and is engaged in developing its wholly owned Malartic Metals Package, Quebec’s newest polymetallic battery minerals district with several areas of mineralization, one of which is the nickel, cobalt, copper and zinc mineralized Victoria structure. This structure boasts approximately 20 kilometers of strike with surface mineralization, limited drilling, road access and hydroelectric power.

For more information, visit www.RenforthResources.com.

NOTE TO INVESTORS: The latest news and updates relating to RFHRF are available in the company’s newsroom at https://ibn.fm/RFHRF